Einzeltreffer — DigiBib

The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.

Titel:	UBIQUITIN LIGASE KPC1 PROMOTES PROCESSING OF P105 NF-KAPPAB1 TO P50, ELICITING STRONG TUMOR SUPPRESSION
Link:	Zum Volltext
Veröffentlichung:	2023
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20230095010 Publication Date: March 30, 2023 Appl. No: 17/887828 Application Filed: August 15, 2022 Assignees: Technion Research & Development Foundation Limited. (Haifa, IL) Claim: 1. A method of treating cancer in a subject comprising the step of administering to said subject a therapeutically effective amount of a peptide comprising p50, peptide which is at least about 70% homologous to the p50 sequence as set forth in SEQ ID NO: 3 or an agent which upregulates p50; a fused protein comprising p50 or the peptide which is at least about 70% homologous to the p50 sequence as set forth in SEQ ID NO: 3 or the agent which up-regulates p50; or a complex comprising p50, the peptide which is at least about 70% homologous to the p50 sequence as set forth in SEQ ID NO: 3 or the agent which upregulates p50 or the fused protein that comprises p50, the peptide which is at least about 70% homologous to the p50 sequence as set forth in SEQ ID NO: 3 or the agent which upregulates p50, to a subject in need, thereby treating cancer. Claim: 2. The method of any one of claim 1, wherein the cancer is breast cancer, bone osteosarcoma or glioblastoma. Current International Class: 61; 61; 07; 12

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

UBIQUITIN LIGASE KPC1 PROMOTES PROCESSING OF P105 NF-KAPPAB1 TO P50, ELICITING STRONG TUMOR SUPPRESSION